高级搜索

多西他赛为主与奥沙利铂为主一线治疗晚期Lauren分型胃癌的疗效对比

毛志远, 郭晓川, 张婷婷, 苏 丹, 王李杰, 白 莉

毛志远, 郭晓川, 张婷婷, 苏 丹, 王李杰, 白 莉. 多西他赛为主与奥沙利铂为主一线治疗晚期Lauren分型胃癌的疗效对比[J]. 肿瘤防治研究, 2014, 41(06): 635-640. DOI: 10.3971/j.issn.1000-8578.2014.06.028
引用本文: 毛志远, 郭晓川, 张婷婷, 苏 丹, 王李杰, 白 莉. 多西他赛为主与奥沙利铂为主一线治疗晚期Lauren分型胃癌的疗效对比[J]. 肿瘤防治研究, 2014, 41(06): 635-640. DOI: 10.3971/j.issn.1000-8578.2014.06.028
shu
MAO Zhiyuan, GUO Xiaochuan, ZHANG Tingting, SU Dan, WANG Lijie, BAI Li. Comparison of Docetaxel-based and Oxaliplatin-based First-line Treatment for Advanced Gastric Cancer in Lauren Type[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 635-640. DOI: 10.3971/j.issn.1000-8578.2014.06.028
Citation: MAO Zhiyuan, GUO Xiaochuan, ZHANG Tingting, SU Dan, WANG Lijie, BAI Li. Comparison of Docetaxel-based and Oxaliplatin-based First-line Treatment for Advanced Gastric Cancer in Lauren Type[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 635-640. DOI: 10.3971/j.issn.1000-8578.2014.06.028
shu

多西他赛为主与奥沙利铂为主一线治疗晚期Lauren分型胃癌的疗效对比

  • 100853 北京，中国人民解放军总医院肿瘤内科

详细信息
    作者简介:

    毛志远（1983-），男，硕士在读，主要从事消化系统肿瘤的研究

  • 中图分类号: R735.2

Comparison of Docetaxel-based and Oxaliplatin-based First-line Treatment for Advanced Gastric Cancer in Lauren Type

  • Department of Oncology,The Chinese People's Liberation Army General Hospital,Beijing 100853,China

HTML全文

    摘要
  • 摘要: 目的 探讨以多西他赛为主的化疗方案与以奥沙利铂为主的化疗方案一线治疗晚期胃癌在Lauren 分型中的临床疗效。方法 收集中国人民解放军总医院311例晚期胃癌患者，对有随访结果的199例进行Lauren分型，其中肠型88例，弥漫型105例，混合型6例。一线以多西他赛为主化疗方案的109例，以奥沙利铂为主化疗方案的54例，其他化疗方案36例。中位可评价周期数为4周期，且疗效可评价。结果 在肠型组中以多西他赛为主化疗的客观有效率（ORR）为26.7%，疾病控制率（DCR）为86.7%，中位疾病无进展期（mPFS）为4.50月，中位总生存期（mOS）为15.67月；在肠型组中以奥沙利铂为主化疗的客观有效率（ORR）为15.0%，疾病控制率（DCR）为85.0%，中位疾病无进展期（mPFS）为6.33月，中位总生存期（mOS）为21.50月。在弥漫型组中以多西他赛为主化疗的客观有效率（ORR）为18.9%，疾病控制率（DCR）为67.9%，中位疾病无进展期（mPFS）为2.53月，中位总生存期（mOS）为7.23月；在弥漫型组中以奥沙利铂为主化疗的客观有效率（ORR）为10.7%，疾病控制率（DCR）为67.9%，中位疾病无进展期（mPFS）为3.57月，中位总生存期（mOS）为7.23月。因混合型病例较少，故未列入统计之列。结论 弥漫型胃癌较肠型胃癌的预后差。以多西他赛为主化疗方案和以奥沙利铂为主化疗方案在胃癌Lauren分型的肠型和弥漫型中ORR、DCR、mPFS以及mOS的比较，差异均无统计学意义（P＞0.05）。

     

    Abstract: Objective To evaluate the clinical effi cacy of Docetaxel-based and Oxaliplatin-based chemotherapy in the fi rst-line treatment of advanced gastric cancer（AGC）in different Lauren types. Methods Retrospective analysis of 311 AGC cases in PLA hospital was involved. Among them, 199 cases had follow-up results, in which, 88 cases were intestinal types, 105 were diffuse types and 6 were mixed types. One hundred and nine and 54 cases were treated with Docetaxel-based and Oxaliplatin-based fi rst line chemotherapy, respectively. Other 36 cases accepted other regimens. The median evaluated cycles were 4 cycles and the effi ciency were evaluated. Results The overall response rate (ORR) of Docetaxel-based chemotherapy in intestinal-type group was 26.7%, the disease control rate (DCR) was 86.7%, the median progression-free survival (mPFS) was 4.50 months, and median overall survival (mOS) was 15.67 months. The ORR of Oxaliplatin-based chemotherapy was 15.0%, the DCR was 85.0%, the mPFS was 6.33 months, and the mOS was 21.50 months. The ORR of Docetaxel-based chemotherapy in diffuse-type group was 18.9%, the DCR was 67.9%, the mPFS was 2.53 months, and the mOS was 7.23 months. The ORR of Oxaliplatin-based chemotherapy was 10.7%, the DCR was 67.9%, the mPFS was 3.57 months, and the mOS was 7.23 months. Considering the number of patients was too small, the data of mixed type was not analyzed. Conclusion Patients with diffuse-type AGC have poorer prognosis than those with intestinal-type. There is no statistically signifi cant difference of ORR, DCR, mPFS and mOS between two different chemotherapy groups of advanced gastric cancer in Lauren type(P > 0.05).

     

    • HTML全文
    • 参考文献(17)
  • [1] Glimelius B,Ekström K, Hoffman K,et al．Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer[J]. Ann Oncol,1997,8(2):163-8．
    [2] Yu YY.The Pathological classification of gastric cancer and its relationship with outcome of patients[J].Wai Ke Li Lun Yu Shi Jian, 2011,16(3):240-3.[于颖彦.胃癌的病理分型与预后[J].外科 理论与实践 ,2011,16(3):240-3.]
    [3] Li YC, Wu XT. Relationship Between Pathologic Feature and Biological Behavior of Gastric Cancer[J]. Zhongguo Pu Wai Ke Ji Chu Yu Lin Chuang Za Zhi, 2006,13(1):120-2.[李月春，伍晓 汀.胃癌病理学与生物学特征的关系[J]. 中国普外科基础与临 床杂志, 2006,13(1):120-2.]
    [4] Parkin DM,Bray F,Ferlay J,et al．Global cancer statistics， 20 02[J].CA Cancer J Clin,2005,55(2):74-108.
    [5] Van Cutsem EThe treatment of advanced gastric cancer：new fi ndings on the activity of the taxanes[J]Oncologist,2004,9 Suppl 2: 9-15.
    [6] Rivera F,Vega-Villegas ME,López-Brea MF．Chemotherapy of advanced gastric cancer[J].Cancer Treat Rev,2007,33(4):315-24.
    [7] Xiao JX,Zhang L,Qiu F,et al. A Phase II study of capecitabine plus oxaliplatin as first-Line chemotherapy in elderly patients with advanced gastric cancer[J]. Chemotherapy, 2012,58(1):1-7.
    [8] Yang T，Shen X，Tang X，et al．Phase II trial of oxaliplatin plus oral capecitabine as fi rst-line chemotherapy for patients with advanced gastric cancer[J]. Tumori, 2011,97(4):466-72.
    [9] Kim GM, Jeung HC, Rha SY,et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer[J]. Eur J Cancer,2012,48（4）:518-26.
    [10] Oh SY, Kwon HC, Jeong SH,et al. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer[J]. Invest New Drugs,2012,30(1):350-6.
    [11] Kunisaki C, Takahashi M, Makino H,et al. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as fi rstline treatment for advanced gastric cancer[J]. Cancer Chemother Pharmacol,2011,67(6):1363-8.
    [12] Jeung HC, Rha SY, Im CK,et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy[J]. Cancer, 2011,117(10):2050-7.
    [13] Roy A, Cunningham D, Hawkins R,et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study[J]. Br J Cancer,2012,107(3):435-41.
    [14] Kang YK, Ryu MH, Yoo C,et al. Phase I/II study of a combination of docetaxel, capecitabine,and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer[J]. Cancer Chemother Pharmacol,2011,67(6):1435-43.
    [15] Chi Y, Ren JH, Yang L,et al. Phase II clinical study on the modifi ed DCF regimen for treatment of advanced gastric carcinoma[J]. Chin Med J(Engl),2011,124(19):2997-3002.
    [16] Amarantidis K, Xenidis N, Chelis L,et al. Docetaxel plus oxaliplatin in combination with capecitabine as fi rst-line treatment for advanced gastric cancer[J]. Oncology,2011,80(5-6):359-65.
    [17] Chen JS, Chen YY, Huang JS,et al. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer[J]. Gastric Cancer,2012,15(1):49-55.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1169
  • HTML全文浏览量:  303
  • PDF下载量:  810
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-06-04
  • 修回日期:  2013-10-22
  • 刊出日期:  2014-06-24

目录

摘要
HTML全文
    参考文献(17)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11648775 今日访问：16124

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭